Posted by Michael Wonder on 02 Jun 2021
Kedrion and Kamada announce FDA approval of Kedrab label update, confirming safety and effectiveness in children
2 June 2021 - New FDA approval based on safety and effectiveness of Kedrab in the paediatric population demonstrated in a U.S. post-marketing clinical trial.
Kedrion Biopharma and Kamada announced today the U.S. FDA has approved a label update for Kedrab (rabies immune clobulin [human]), establishing the product’s safety and effectiveness in children.
